A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
strengthen requirements for postapproval studies for 
drugs approved using accelerated approval, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Accelerated Approval 
4
Integrity Act of 2022’’. 
5
22:42 Mar 09, 2022
H6963
2 
•HR 6963 IH
SEC. 2. POSTAPPROVAL STUDIES REQUIRED FOR ACCELER-
1
ATED APPROVAL DRUGS. 
2
(a) IN GENERAL.—Section 506(c) of the Federal 
3
Food, Drug, and Cosmetic Act (21 U.S.C. 356(c)) is 
4
amended— 
5
(1) in paragraph (2)— 
6
(A) in the matter preceding subparagraph 
7
(A), by striking ‘‘may be subject to 1 or both 
8
of’’ and inserting ‘‘shall be subject to’’; 
9
(B) by amending subparagraph (A) to read 
10
as follows: 
11
‘‘(A) POSTAPPROVAL STUDIES.— 
12
‘‘(i) IN GENERAL.—The sponsor of a 
13
product approved under accelerated ap-
14
proval shall— 
15
‘‘(I) conduct appropriate, ade-
16
quate, 
and 
well-controlled 
post-
17
approval studies to verify and describe 
18
the predicted effect on irreversible 
19
morbidity or mortality or other clin-
20
ical benefit; and 
21
‘‘(II) submit reports on such 
22
studies in accordance with section 
23
506B. 
24
‘‘(ii) 
AGREEMENT.—The 
Secretary 
25
and the sponsor shall enter into an agree-
26
22:42 Mar 09, 2022
H6963
3 
•HR 6963 IH
ment regarding the required conduct of 
1
such studies prior to the Secretary approv-
2
ing a product under accelerated approval. 
3
Such agreement may include requirements 
4
regarding enrollment targets, study pro-
5
tocol, and milestones, including the target 
6
date of study completion. 
7
‘‘(iii) STUDIES
BEGUN
BEFORE
AP-
8
PROVAL.—The Secretary may— 
9
‘‘(I) require such studies to be 
10
underway prior to approval; and 
11
‘‘(II) refuse to approve a product 
12
under accelerated approval until such 
13
studies are underway.’’; and 
14
(C) in subparagraph (B), by striking ‘‘(B) 
15
That the sponsor’’ and inserting the following: 
16
‘‘(B) 
PROMOTIONAL
MATERIALS.—The 
17
sponsor of a product approved under acceler-
18
ated approval shall’’; and 
19
(2) by striking paragraph (3) and inserting the 
20
following: 
21
‘‘(3) 
EXPEDITED
WITHDRAWAL
OF
AP-
22
PROVAL.— 
23
‘‘(A) IN
GENERAL.—The Secretary may 
24
withdraw approval of a product approved under 
25
22:42 Mar 09, 2022
H6963
4 
•HR 6963 IH
accelerated approval using expedited procedures 
1
described in subparagraph (B), if— 
2
‘‘(i) the sponsor fails to conduct any 
3
required postapproval study of the product 
4
with due diligence; 
5
‘‘(ii) the sponsor fails to achieve 
6
agreed upon enrollment targets, mile-
7
stones, or timely study completion; 
8
‘‘(iii) the sponsor fails to submit re-
9
ports in accordance with section 506B; 
10
‘‘(iv) a study required to verify and 
11
describe the predicted effect on irreversible 
12
morbidity or mortality or other clinical 
13
benefit of the product fails to verify and 
14
describe such effect or benefit; 
15
‘‘(v) other evidence demonstrates that 
16
the product is not shown to be safe or ef-
17
fective under the conditions of use; or 
18
‘‘(vi) the sponsor disseminates false or 
19
misleading promotional materials with re-
20
spect to the product. 
21
‘‘(B) 
EXPEDITED
PROCEDURES
DE-
22
SCRIBED.—Expedited procedures described in 
23
this subparagraph— 
24
‘‘(i) shall consist of— 
25
22:42 Mar 09, 2022
H6963
5 
•HR 6963 IH
‘‘(I) providing the sponsor due 
1
notice and an opportunity for written 
2
appeal to the Commissioner of Food 
3
and Drugs; and 
4
‘‘(II) an opportunity for public 
5
comment on the notice proposing to 
6
withdraw approval; and 
7
‘‘(ii) may include, at the Secretary’s 
8
discretion, convening and consulting an ad-
9
visory committee. 
10
‘‘(C) AUTOMATIC
EXPIRATION.—The ap-
11
proval of a product approved under accelerated 
12
approval after the date of enactment of the Ac-
13
celerated Approval Integrity Act of 2022 shall 
14
automatically expire 1 year after any target 
15
date of study completion included in an agree-
16
ment described in clause (ii) of paragraph 
17
(2)(A), and in no case later than 5 years after 
18
the date on which the product is approved, un-
19
less— 
20
‘‘(i) a study required to verify and de-
21
scribe the predicted effect on irreversible 
22
morbidity or mortality or other clinical 
23
benefit of the product has verified that 
24
predicted effect; or 
25
22:42 Mar 09, 2022
H6963
6 
•HR 6963 IH
‘‘(ii) the Secretary has determined 
1
that adequate progress has been made on 
2
completion of postapproval studies required 
3
under paragraph (2)(A). 
4
‘‘(4) LABELING.— 
5
‘‘(A) IN
GENERAL.—Subject to subpara-
6
graph (B), the label for a product approved 
7
under accelerated approval shall include— 
8
‘‘(i) a statement indicating that the 
9
product was approved under accelerated 
10
approval; 
11
‘‘(ii) a statement indicating that con-
12
tinued approval of the product is subject to 
13
postmarketing studies to verify clinical 
14
benefit; 
15
‘‘(iii) identification of the clinical end-
16
point that is under study and any known 
17
limitations of that surrogate or inter-
18
mediate endpoint in determining clinical 
19
benefit; 
20
‘‘(iv) a succinct description of the 
21
product and any uncertainty about antici-
22
pated clinical benefit and a discussion of 
23
available evidence with respect to such clin-
24
ical benefit; and 
25
22:42 Mar 09, 2022
H6963
7 
•HR 6963 IH
‘‘(v) any other information required 
1
by the Secretary in the order approving the 
2
product. 
3
‘‘(B) APPLICABILITY.—The labeling re-
4
quirements of subparagraph (A) shall apply 
5
only to products approved under accelerated ap-
6
proval for which the predicted effect on irre-
7
versible morbidity or mortality or other clinical 
8
benefit has not been verified.’’. 
9
(b) REPORTS OF POSTMARKETING STUDIES.—Sec-
10
tion 506B(a) of the Federal Food, Drug, and Cosmetic 
11
Act (21 U.S.C. 356b(a)) is amended— 
12
(1) by redesignating paragraph (2) as para-
13
graph (3); and 
14
(2) by inserting after paragraph (1) the fol-
15
lowing: 
16
‘‘(2) 
ACCELERATED
APPROVAL.—Notwith-
17
standing paragraph (1), a sponsor of a drug ap-
18
proved under accelerated approval shall submit to 
19
the Secretary a report of the progress of any study 
20
required under section 506(c), including progress to-
21
ward any agreed upon enrollment targets, mile-
22
stones, and other information as required by the 
23
Secretary, not later than 90 days after the approval 
24
of such drug and not less frequently than every 90 
25
22:42 Mar 09, 2022
H6963
8 
•HR 6963 IH
days thereafter, until the study is completed or ter-
1
minated.’’. 
2
(c) ENFORCEMENT.—Section 301 of the Federal 
3
Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amend-
4
ed by inserting after paragraph (eee) the following: 
5
‘‘(fff) The failure of a sponsor of a product approved 
6
under accelerated approval pursuant to section 506(c)— 
7
‘‘(1) to conduct with due diligence any post-
8
approval study required under section 506(c) with 
9
respect to such product; or 
10
‘‘(2) to submit timely reports with respect to 
11
such 
product 
in 
accordance 
with 
section 
12
506B(a)(2).’’. 
13
Æ 
22:42 Mar 09, 2022
H6963
